Zurcher Kantonalbank Zurich Cantonalbank Grows Holdings in DaVita Inc. (NYSE:DVA)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in DaVita Inc. (NYSE:DVA - Free Report) by 28.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 95,657 shares of the company's stock after purchasing an additional 21,205 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.10% of DaVita worth $10,021,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DVA. Resources Management Corp CT ADV grew its holdings in DaVita by 5,900.0% during the 2nd quarter. Resources Management Corp CT ADV now owns 300 shares of the company's stock valued at $30,000 after buying an additional 295 shares in the last quarter. Parkside Financial Bank & Trust increased its position in DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company's stock worth $35,000 after purchasing an additional 147 shares during the last quarter. Harbor Investment Advisory LLC bought a new stake in DaVita in the third quarter worth $34,000. Hanseatic Management Services Inc. purchased a new stake in DaVita during the third quarter valued at $36,000. Finally, FinTrust Capital Advisors LLC lifted its position in DaVita by 242.3% during the third quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company's stock valued at $67,000 after purchasing an additional 504 shares during the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Trading Up 1.4 %

Shares of NYSE DVA traded up $1.71 during mid-day trading on Friday, reaching $127.82. The company had a trading volume of 487,093 shares, compared to its average volume of 470,359. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $141.54. The business's 50-day moving average is $130.68 and its 200-day moving average is $109.12. The stock has a market cap of $11.21 billion, a price-to-earnings ratio of 17.27, a price-to-earnings-growth ratio of 1.12 and a beta of 1.04. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The company had revenue of $3.15 billion for the quarter, compared to analysts' expectations of $3.01 billion. During the same quarter in the prior year, the firm earned $1.11 earnings per share. DaVita's revenue was up 7.8% compared to the same quarter last year. Equities analysts expect that DaVita Inc. will post 9.23 earnings per share for the current year.

Insider Activity

In other news, COO Michael David Staffieri sold 29,488 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the transaction, the chief operating officer now directly owns 37,687 shares in the company, valued at $4,515,279.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company's stock, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael David Staffieri sold 29,488 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the sale, the chief operating officer now directly owns 37,687 shares of the company's stock, valued at approximately $4,515,279.47. The disclosure for this sale can be found here. In the last quarter, insiders sold 134,540 shares of company stock worth $16,551,071. 1.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DVA. Truist Financial increased their price target on shares of DaVita from $130.00 to $135.00 and gave the company a "hold" rating in a report on Tuesday, February 20th. UBS Group boosted their target price on DaVita from $113.00 to $134.00 and gave the company a "buy" rating in a research report on Wednesday, February 14th. Barclays started coverage on DaVita in a research report on Wednesday, March 6th. They issued an "equal weight" rating and a $133.00 price target for the company. TheStreet upgraded shares of DaVita from a "c+" rating to a "b-" rating in a research report on Wednesday, February 7th. Finally, StockNews.com lowered shares of DaVita from a "strong-buy" rating to a "buy" rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of "Moderate Buy" and an average target price of $118.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.